
Opinion|Videos|November 20, 2025
Using TDMs to Improve Care and Communication
Author(s)Jonathan M. Meyer, MD, DLFAPA
Reviewing TDM’s evidence-based rationale, its clinical utility, and connection to outcomes.
Advertisement
This video covers the following questions:
- Can you walk us through the typical therapeutic range—and what factors can influence individual variability?
- How can TDM help clinicians differentiate between treatment resistance due to pharmacokinetic factors (like metabolism) versus true nonresponse? and What role does TDM play in preventing toxicity, including dose-related adverse effects such as seizures or sedation?
- How might TDM support patient adherence and shared decision-making in clinical practice?
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
NDA Submission: Olanzapine Extended-Release Injectable Suspension for Treatment of Schizophrenia
2
FDA Accepts NDA for TRN-257 for Treatment of Narcolepsy and Idiopathic Hypersomnia
3
Evenamide for Treatment-Resistant Schizophrenia: Initiation of ENIGMA-TRS 2 Phase 3 Clinical Study
4
An Impressive Year: Looking Back on Our 40th Anniversary
5









